Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Savella Clear all
Completed Phase 4 Interventional Results available

Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)

NCT03128021
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram Pill, Placebo, Levomilnacipran Pill
Drug · Other
Lead sponsor
Howard Aizenstein
Other
Eligibility
60 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 24, 2026, 5:55 AM EDT
Completed Not applicable Interventional Results available

Novel Medication as a Potential Smoking Cessation Aid

NCT02265367
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Levomilnacipran, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
25 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 24, 2026, 5:55 AM EDT
Completed Phase 4 Interventional Results available

Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia

NCT01014585
View directory record Official record
Conditions
Fibromyalgia
Interventions
Placebo, Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Not listed
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 24, 2026, 5:55 AM EDT
Terminated Phase 3 Interventional Results available

A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain

NCT01288937
View directory record Official record
Conditions
Idiopathic Peripheral Neuropathy
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 24, 2026, 5:55 AM EDT
Recruiting Phase 2 Interventional

Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression

NCT06591091
View directory record Official record
Conditions
Depression
Interventions
Clemastine Fumarate, Placebo
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
60 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 24, 2026, 5:55 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

The Savella Pregnancy Registry

NCT01026077
View directory record Official record
Conditions
Fibromyalgia
Interventions
Not listed
Lead sponsor
Syneos Health
Other
Eligibility
18 Years and older · Female only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2024
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 24, 2026, 5:55 AM EDT
Completed Not applicable Interventional Results available

Study Evaluated the Effectiveness of Milnacipran to Reduce Pain Levels in Individuals With Chronic Migraine

NCT01393522
View directory record Official record
Conditions
Chronic Migraine
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Timothy Smith
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
St Louis, Missouri • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 24, 2026, 5:55 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Uncovering Neural and Immune Mechanisms of Chronic Pain in Post Treatment Lyme Syndrome

NCT02687165
View directory record Official record
Conditions
Post Treatment Lyme Syndrome (PTLS), Chronic Pain
Interventions
Milnacipran and D-cycloserine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 24, 2026, 5:55 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia

NCT01328002
View directory record Official record
Conditions
Primary Fibromyalgia
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
13 Years to 17 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
47
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Fresno, California + 38 more
Source: ClinicalTrials.gov public record
Updated May 14, 2019 · Synced Oct 24, 2026, 5:55 AM EDT
Completed Phase 4 Interventional Results available

Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)

NCT01780389
View directory record Official record
Conditions
Knee Pain After Total Knee Arthroplasty, Osteoarthritis Pain
Interventions
Open-label flexibly dosed milnacipran
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2015 · Synced Oct 24, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder

NCT02431806
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Levomilnacipran, Fluoxetine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
12 Years to 17 Years
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
48
States / cities
Dothan, Alabama • Tucson, Arizona • Anaheim, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 24, 2026, 5:55 AM EDT
Terminated Phase 2 Interventional Results available

Long-Term Safety and Efficacy Study of Milnacipran in Pediatric Patients With Primary Fibromyalgia

NCT01331109
View directory record Official record
Conditions
Primary Fibromyalgia
Interventions
Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
13 Years to 17 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Bullhead City, Arizona • Fresno, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 24, 2026, 5:55 AM EDT
Completed Phase 4 Interventional Results available

Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism

NCT01337700
View directory record Official record
Conditions
Autism Spectrum Disorder, Asperger Syndrome, Aspergers Syndrome
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 24, 2026, 5:55 AM EDT
Completed Phase 4 Interventional Results available

The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia

NCT01234675
View directory record Official record
Conditions
Sleep Disorders, Fibromyalgia, Sleep
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Mansoor Ahmed M.D.
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Middleburg Heights, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 24, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia

NCT00797797
View directory record Official record
Conditions
Fibromyalgia
Interventions
No Treatment Added, Milnacipran Added
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
60
States / cities
Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2011 · Synced Oct 24, 2026, 5:55 AM EDT
Completed Phase 4 Interventional Results available

Study of Milnacipran in Patients With Inadequate Response to Duloxetine for the Treatment of Fibromyalgia

NCT01077375
View directory record Official record
Conditions
Fibromyalgia
Interventions
Placebo, Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
26
States / cities
Sacramento, California • Cromwell, Connecticut • Danbury, Connecticut + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2012 · Synced Oct 24, 2026, 5:55 AM EDT
Not listed Phase 4 Interventional

Preventive Treatment of Episodic and Chronic Migraine

NCT01319825
View directory record Official record
Conditions
Migraine With Aura, Migraine Without Aura, Chronic Migraine
Interventions
milnacipran
Drug
Lead sponsor
California Medical Clinic for Headache
Other
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2011 · Synced Oct 24, 2026, 5:55 AM EDT
Completed Phase 4 Interventional Results available

Effect of Milnacipran on Pain in Fibromyalgia

NCT01288807
View directory record Official record
Conditions
Fibromyalgia
Interventions
Milnacipram
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 24, 2026, 5:55 AM EDT
Completed Phase 2Phase 3 Interventional Results available

The Effect of Milnacipran in Patients With Fibromyalgia

NCT01108731
View directory record Official record
Conditions
Fibromyalgia
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years to 68 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 30, 2016 · Synced Oct 24, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Savella in Treatment for Provoked Vestibulodynia

NCT01304589
View directory record Official record
Conditions
Vestibulodynia, Vulvodynia
Interventions
Milnacipran
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 24, 2026, 5:55 AM EDT
Completed Phase 1 Interventional

Effects of Milnacipran on Widespread Mechanical and Thermal Hyperalgesia of Fibromyalgia Patients

NCT01294059
View directory record Official record
Conditions
Fibromyalgia
Interventions
Milnacipran
Drug
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 24, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial

NCT01829243
View directory record Official record
Conditions
Fibromyalgia, Neurocognition
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 24, 2026, 5:55 AM EDT
Completed Phase 3 Interventional Results available

A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring

NCT00618956
View directory record Official record
Conditions
Fibromyalgia
Interventions
Milnacipran hydrochloride, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Pismo Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2009 · Synced Oct 24, 2026, 5:55 AM EDT
Not listed Phase 4 Interventional

Study to Evaluate the Efficacy of Milnacipran in the Treatment of Pain Due to Osteoarthritis

NCT01329406
View directory record Official record
Conditions
Osteoarthritis
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Analgesic Solutions
Industry
Eligibility
21 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Natick, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2011 · Synced Oct 24, 2026, 5:55 AM EDT